Trials / Completed
CompletedNCT04350736
First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Theravance Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1 study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics of single (Part A and B) and multiple (Part B) doses of inhaled TD-0903.
Conditions
- Acute Lung Injury (ALI) Associated With COVID-19
- Inflammatory Lung Conditions Associated With COVID-19
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-0903 | Study drug to be administered by inhalation |
| DRUG | Placebo | Placebo to be administered by inhalation |
Timeline
- Start date
- 2020-04-23
- Primary completion
- 2020-06-24
- Completion
- 2020-07-01
- First posted
- 2020-04-17
- Last updated
- 2021-07-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04350736. Inclusion in this directory is not an endorsement.